<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202952</url>
  </required_header>
  <id_info>
    <org_study_id>HEC110114-P-02</org_study_id>
    <nct_id>NCT04202952</nct_id>
  </id_info>
  <brief_title>The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects</brief_title>
  <acronym>HEC110114</acronym>
  <official_title>A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability， Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending
      Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114
      Tablets in HCV-infected Subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 24 evaluable patients will be enrolled in this study. The study randomly divided
      into three dose groups and HEC110114 tablets planned dose levels are 600, 800, and 1200 mg,
      sofosbuvir tablets planned dose levels are 400 mg .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">September 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From Days 1-10</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Time to Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 T1/2 T1/2 T1/2</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Apparent Half-Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>At pre-defined intervals from Days 1-10</time_frame>
    <description>HCV RNA declined from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC110114 Tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir Tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>1200 mg multiple doses</arm_group_label>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the informed consent form before the trial and fully understand the contents of
             the trial, the process and possible adverse reactions;

          -  Be able to complete the study according to the trail protocol;

          -  Subjects (including partners) have no pregnancy plan within six months after the last
             dose of study drug and voluntarily take effective contraceptive measures;

          -  Male subjects and must be 18 to 65 years of age inclusive;

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50
             kg for males and ≥45 kg for females;

          -  No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as
             Simeprevir, Sofosbuvir, Daclatasvir etc;

          -  HCV RNA ≥10*5 IU/mL at screening (Roche COBAS Taqman);

          -  Chronic genotype 1-6 HCV Infection, multiple genotypes, subtype unidentifiable or
             others ;

          -  Serum ALT ≤5 times ULN.

        Exclusion Criteria:

          -  Allergies constitution ( multiple drug and food allergies);

          -  History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25
             mL of spirits or 100 mL of wine);

          -  Donation or loss of blood over 450 mL within 3 months prior to screening;

          -  History of any non-HCV liver diseases, including but not limited to hemochromatosis,
             primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic
             hepatitis, non-alcoholic steatohepatitis, etc;

          -  12-lead ECG with clinically significant;

          -  Pregnant or lactating women;

          -  Creatinine clearance &lt; 60 mL/min;

          -  Subjects deemed unsuitable by the investigator for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junqi Niu, Doctor</last_name>
    <phone>13756661205</phone>
    <email>junqiniu@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanhua Ding, Doctor</last_name>
    <phone>18186879768</phone>
    <email>dingyanhua2003@126.com</email>
  </overall_contact_backup>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

